Treatment for Type 2 Diabetes: Saxaglipt

Main Article Content

Methinee Intarates
Naeti Suksomboon

Abstract

No Abstract

Article Details

Section
Pharmaceutical Practice

References

Ahren, B. Clinical results of treating type 2 diabeticpatients with sitagliptin, vildagliptin orsaxagliptin--diabetes control and potentialadverse events. Best Pract Res Clin EndocrinolMetab 2009; 23(4): 487-498.

Ammirati, MJ, Andrews, KM, et al. (3,3-Difluoro-pyrrolidin-1-yl)-[(2S,4S)-(4-(4-pyrimidin-2-yl-piperazin-1-y l)-pyrrolidin-2-yl]-methanone: a potent, selective, orallyactive dipeptidyl peptidase IV inhibitor. BioorgMed Chem Lett 2009; 19(7): 1991-1995.

Anonymous. Saxagliptin (Onglyza) for type 2diabetes. Med Lett Drugs Ther 2009;51(1324): 85-886.

Barnett, AH. New treatments in type 2 diabetes: afocus on the incretin-based therapies. ClinEndocrinol (Oxf) 2009; 70(3): 343-353.

Chacra, AR, Tan, GH, et al. Saxagliptin added to asubmaximal dose of sulphonylurea improvesglycaemic control compared with uptitration ofsulphonylurea in patients with type 2 diabetes:a randomised controlled trial. Int J Clin Pract2009; 63(9): 1395-1406.

Combettes, MM. GLP-1 and type 2 diabetes:physiology and new clinical advances. CurrOpin Pharmacol 2006; 6(6): 598-605.

Deacon, CF and Holst, JJ. Saxagliptin: a new dipeptidylpeptidase-4 inhibitor for the treatment of type2 diabetes. Adv Ther 2009; 26(5):488-499.

DeFronzo, RA, Hissa, MN, et al. The efficacy andsafety of saxagliptin when added to metformintherapy in patients with inadequately controlledtype 2 diabetes with metformin alone.Diabetes Care 2009; 32(9): 1649-1655.

Focosi, D, Kast, RE, et al. Enhancement of hematopoietic stem cell engraftment by inhibition ofCXCL12 proteolysis with sitagliptin, an oraldipeptidyl-peptidase IV inhibitor: a report in acase of delayed graft failure. Leuk Res 2009;33(1): 178-181.

Goke, B, Gallwitz, B, et al. Saxagliptin is non-inferiorto glipizide in patients with type 2 diabetesmellitus inadequately controlled on metforminalone: a 52-week randomised controlled trial.International Journal of Clinical Practice 2010;64(12): 1619-1631.

Havale, SH and Pal, M. Medicinal chemistryapproaches to the inhibition of dipeptidylpeptidase-4 for the treatment of type 2diabetes. Bioorg Med Chem 2009; 17(5):1783-1802.

Hollander, P, Li, J, et al. Saxagliptin added to athiazolidinedione improves glycemic control inpatients with type 2 diabetes and inadequatecontrol on thiazolidinedione alone. J ClinEndocrinol Metab 2009; 94(12):4810-4819.

Kulasa, K and Edelman, S. Saxagliptin: the evidencefor its place in the treatment of type 2 diabetesmellitus. Core Evid 2010; 5: 23-37.

Mulakayala, N, Reddy Ch, U, et al. Synthesis ofdipeptidyl peptidase-4 inhibitors: a briefoverview. Tetrahedron 2010; 66(27-28):4919-4938.

Rosenstock, J, Aguilar-Salinas, C, et al. Effect ofsaxagliptin monotherapy in treatment-naivepatients with type 2 diabetes. Curr Med ResOpin 2009; 25(10): 2401-2411.

Sharma, M. Role of saxagliptin as monotherapy oradjunct therapy in the treatment of type 2diabetes. Ther Clin Risk Manag 2010; 6:233-237.

Singh, S, Sethi, S, et al. RBx-0597, a potent,selective and slow-binding inhibitor of dipeptidylpeptidase-IV for the treatment of type 2diabetes. Eur J Pharmacol 2010; [Epub aheadof print].

Tahrani, AA, Piya, MK, et al. Saxagliptin: a newDPP-4 inhibitor for the treatment of type 2diabetes mellitus. Adv Ther 2009; 26(3):249-262.

Tahrani, AA, Piya, MK, et al. Glycaemic control intype 2 diabetes: targets and new therapies.Pharmacol Ther 2010; 125(2): 328-361.

Thornberry, NA and Gallwitz, B. Mechanism of actionof inhibitors of dipeptidyl-peptidase-4(DPP-4). Best Pract Res Clin EndocrinolMetab 2009; 23(4): 479-486.

Yu, BS and Wang, AR. Glucagon-like peptide 1 basedtherapy for type 2 diabetes. World J Pediatr2008; 4(1): 8-13.